Search results for astrazeneca
AstraZeneca announced that it has filed patent infringement actions in United States District Court, District of Delaware, against seven generic drug
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
AstraZeneca and Nomura Phase4 Ventures today announced the signing of a deal to form Albireo, a company focused on developing new treatments for gastrointestinal (GI) disorders.
Albireo, based in
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
AstraZeneca today announced it intends to seek reconsideration or reversal of a verdict in the Montgomery County Circuit Court awarding $40 million in compensatory damages and $175 million in punitiv
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
AstraZeneca today announced that its HORIZON III Phase II/III head-to-head study of RECENTIN™ (cediranib, AZD2171) with chemotherapy versus bevacizumab (Avastin™) with chemotherapy in patients with f
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
AstraZeneca announced a trial date has been set for patent litigation in the US District Court for the District of New Jersey against Teva Pharmaceutical Industries Ltd. and Sandoz, Inc. alleging inf
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
AstraZeneca today announced it has decided to stop the CRESTOR JUPITER clinical study early based on a recommendation from an Independent Data Monitoring Board and the JUPITER Steering Committee, whi
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
AstraZeneca today announced it has entered into a settlement agreement in its Nexium patent infringement litigation against Ranbaxy Laboratories Ltd. and its affiliates ("Ranbaxy"). The agreement s
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Sales in the first quarter increased by 4 percent at CER, or 10 percent on an as reported basis. Sales in the US were up 5 percent; the inclusion of MedImmune sales in the quarter more than offset th
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
AstraZeneca today announced submission of a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA) to seek approval of a new indication for SYMBICORT® (budesonide/formo
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
AstraZeneca and Columbia University Medical Center in New York announced that they have entered into a strategic research collaboration in metabolic related diseases, to develop novel therapeutics pr
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
